Kuros Biosciences was granted European Patent No. EP3021878, Method for producing an osteoinductive calcium phosphate and products thus obtained, protecting MagnetOs bone graft substitute.
The production method creates a surface topography that "instructs" stem cells and osteoprogenitor cells to differentiate into bone-forming cells. The biphasic calcium phosphate materials on which MagnetOs is based have been shown equivalence to autograft in clinically-relevant preclinical models.
MagnetOs Granules have CE Mark approval as a bone void filler for orthopaedic, craniomaxillofacial and dental applications with an osteoinductive claim. In the U.S., granule and putty formats have FDA 510(k) clearance with an osteoconductive claim for use with autograft as a bone graft extender in the posterolateral spine.
Sources: Kuros Biosciences AG; ORTHOWORLD Inc.